Nav: Home

Kidneys infected with hepatitis C can be safely transplanted into healthy recipients

September 02, 2020

BOSTON - Kidneys from deceased donors with hepatitis C virus (HCV) infection can be safely transplanted into noninfected recipients when a regimen of direct-acting antiviral therapies is initiated as early as two days after the transplant, according to a study from Massachusetts General Hospital (MGH). In a multi-center clinical trial reported in the Journal of the American Society of Nephrology, MGH researchers found that each of 30 kidney recipients were cured of HCV with no serious side effects attributable to the antiviral therapy, and that nearly all maintained excellent allograft function at six months.

"We successfully treated the hepatitis C virus in kidneys transplanted from HCV-positive donors by using the antiviral agents glecaprevir and pibrentasvir as part of an eight-week course of daily dosing," says Meghan Sise, MD, investigator in the Division of Nephrology at MGH and co-first author of the study. "These findings could carry a strong message to the many transplant centers that are still wary about or resistant to using kidneys from HCV-infected donors. We've shown that these so-called donor positive to recipient negative transplants can be done safely and effectively through early antiviral intervention."

Nearly 95,000 people in the U.S. are currently waiting for kidney transplant, most suffering progressive health deterioration. For some groups, including patients over 60, death is a greater certainty than a transplant. Given this significant public health problem, the U.S. Department of Health and Human Services set a goal of doubling the number of kidneys available for transplantation by 2030 as part of the Advancing American Kidney Health Initiative. One promising pathway toward that target is reducing the discard of viable human kidneys that now occurs, particularly from deceased individuals with hepatitis C virus infection. The number of those organs has soared over the past five years as a result of mounting deaths from the national opioid epidemic.

The MGH prospective trial is the first multi-center investigation to show the feasibility of donor positive to donor negative transplantation. Known as MYTHIC (Multi-Center Study to Transplant Hepatitis-C Infected Kidneys), the study was conceived and carried out in collaboration with the Perelman School of Medicine at the University of Pennsylvania. Each of the trial's 30 kidney recipients at seven U.S. transplant centers was given an eight-week course of a coformulation of glecaprevir and pibrentasvir, powerful antiviral agents that target two distinct proteins within the virus that are essential to its survival.

While one patient died of complications of sepsis deemed unrelated to trial participation, no severe side effects or liver disease were observed in any patient, and allograft function at six months was excellent. "Many of the patients showed a tiny amount of virus in their blood right after transplant, but that viral load became undetectable or unquantifiable in all recipients of HCV-viremic kidneys by four weeks of treatment, " notes Raymond Chung, MD, investigator in the Liver Center and Gastrointestinal Division at MGH and co-senior author of the study.

The trial's success extends to the development by the research team of an evidence-based clinical protocol for transplanting hepatitis C-infected kidneys that could be used by transplant centers anywhere. "We sought to replace the many homegrown protocols based on varying treatment regimens with one that is sound, uniform and reproducible," explains Chung. "We believe we have succeeded by creating a very simple approach that works in patients."

Researchers are now hopeful that transplant centers will take notice of these encouraging results and the opportunity they afford to increase access to high quality organs by patients in critical need of a kidney transplant. "By showing that these procedures are effective," says Sise, "we're hoping that insurance companies will also see the enormous benefit of making transplants with hepatitis-C infected kidneys uniformly covered and reimbursable. The ultimate goal of everyone should be to increase the quality and quantity of life for patients waiting for a kidney transplant."
-end-
Sise is also a nephrologist and assistant professor of Medicine at Harvard Medical School. Chung is director of Hepatology and the Liver Center at MGH. The study team also included MGH authors Winfred Williams, MD, Nahel Elias, MD, Jenna Gustafson, MS, and co-lead author David Goldberg, MD and, from University of Pennsylvania, co-senior author Peter Reese, MD.

The study was supported by the biopharmaceutical company AbbVie.

About the Massachusetts General Hospital

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH Research Institute conducts the largest hospital-based research program in the nation, with an annual research budget of more than $1 billion and comprises more than 8,500 researchers working across more than 30 institutes, centers and departments. In August 2020 the MGH was named #6 in the nation by U.S. News & World Report in its list of "America's Best Hospitals."

Massachusetts General Hospital

Related Hepatitis Articles:

Busting Up the Infection Cycle of Hepatitis B
Researchers at the University of Delaware have gained new understanding of the virus that causes hepatitis B and the ''spiky ball'' that encloses its genetic blueprint.
Liver cancer: Awareness of hepatitis D must be raised
Scientists from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have studied the most serious consequence of chronic hepatitis: hepatocellular carcinoma.
Hepatitis B: New therapeutic approach may help to cure chronic hepatitis B infection
Researchers at Helmholtz Zentrum München, Technical University of Munich (TUM) and the German Center for Infection Research (DZIF) have developed a novel therapeutic approach to cure chronic hepatitis B.
Anti-hepatitis medicine surprises
A new effective treatment of hepatitis C not only combats the virus, but is also effective against potentially fatal complications such as reduced liver functioning and cirrhosis.
Nanotechnology delivers hepatitis B vaccine
X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response.
Checkmate for hepatitis B viruses in the liver
Researchers at Helmholtz Zentrum München and the Technical University of Munich, working in collaboration with researchers at the University Medical Center Hamburg-Eppendorf and the University Hospital Heidelberg, have for the first time succeeded in conquering a chronic infection with the hepatitis B virus in a mouse model.
How common is Hepatitis C infection in each US state?
Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases.
New strains of hepatitis C found in Africa
The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa.
High stability of the hepatitis B virus
At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.
Findings could lead to treatment of hepatitis B
Researchers have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide.
More Hepatitis News and Hepatitis Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: The Power Of Spaces
How do spaces shape the human experience? In what ways do our rooms, homes, and buildings give us meaning and purpose? This hour, TED speakers explore the power of the spaces we make and inhabit. Guests include architect Michael Murphy, musician David Byrne, artist Es Devlin, and architect Siamak Hariri.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at Radiolab.org/donate.     You can read The Transition Integrity Project's report here.